Powering deeper discovery

Robust, disease-specific datasets powered for statistical significance with whole genome data and detailed longitudinal clinical data.

Accelerating drug target identification, validation, and biomarker discovery

Our disease-specific clinical omics datasets offer genomic data enriched with detailed clinical data and are statistically powered to distinguish signal from noise.

Powered for statistical significance

Robust datasets with data from thousands of pseudonymized participants for many disease, subtypes, and clinical features. Population control dataset with data from 15,000 individuals.

Data privacy and privacy compliance

All participant data are pseudonymized. Clinical, lifestyle, and genomic data provided to biotech partners are strictly access controlled.

Digitize your samples

Whole Genome Sequencing from blood, serum, plasma, fresh tissue or FFPE samples.

Scalable GORdb platform

A genomically-ordered architecture provides the freedom to query the genome in real-time and access private and public genomic databanks.

Powerful analytics crafted for genomics

Analytics and AI trained on multi-omic and phenotypic data. Proven in target discovery, drug response signatures and population genomics.

Participant consent and re-contact

Ability to re-contact participants for follow-up phenotypes, outcomes, and further samples. We ensure participant consent and compliance according to the highest standards of data protection and privacy.

Our differentiated approach

  • Partner with healthcare providers, biopharma, government, foundations, and patient groups
  • Focus on homogeneous populations for better signal-to-noise resolution
  • Use WGS to fully leverage the genome
  • Disease specialists curate and validate deep phenotypic data
  • Supported by our full catalog of products and team of experts

Global Disease Datasets

Breakthrough Contributions

Genuity's AI/ML team publishes its discoveries and novel methods in leading peer-reviewed journals. Below are a selection of recently published breakthrough contributions, from the first successful application of quantum approaches to human multiomics data to in vivo-validated causal biology in cardiovascular disease.